No, but I am a buyer under 14. Every time I have bought low I was able to collect a dividend and benefited from a rebound as well. I will sell some at 16 or 17 if I can get any under 14.
Vette. It is not unexpected that graduate students do not know about biotech. companies. That they do not know general facts about hESC technology like what the source of hESCs being used is a surprising level of ignorance. By the way, it is not just the graduate students. The PhDs in biomedical science I talked to generally displayed the same level of ignorance. I am in Ohio. Maybe in California it is different.
In regards to Stem Cell Inc. Most people do not know what neural stem cells are and do not know that they are adult not embryonic stem cells. When they read about the failure of Stem Cell Inc. they just assumed they were using embryonic stem cells.
Vette. The author might be devious like you said or just plain ignorant. The public at large is ignorant. Most think that the hESCs used are from aborted fetuses. Even many in biomedical science are ignorant about that technology. About 5 years ago I brought up the topic in a small graduate school seminar class which had about 8 students and none knew anything about it.
weg. You are very erratic. A few days ago you were claiming that imetelstat would be approved by the middle of the 1st quarter of 2017.
Vette. Some people claim to be making a moral argument but have another agenda. Those who make money in health care industries that would lose money if people with paralysis and other afflictions could be treated with hESCs do not want to see the technology advance. There are a lot of political and religious puppets protecting agendas.
I was going to write a message debunking the article but they wanted my life history to post. The writer starts out with the lie that StemCell Inc was using embryonic stem cells. In fact their failed trial used Adult neural stem cells. Then there was a discussion about fetal stem cells. Asterias does not use fetal stem cells and it has been determine for years that fetal stem cells are a poor source of stem cells. They are too far differentiated and hard to purify. Blastocytic stem cells are the method of choice and there are hundreds of thousands of them thrown in the trash yearly at IVF clinics. All of the OPCs in both the Geron and Asterias study came from one blastocysts. When the OPCs were held by Geron a scientist there said they had enough frozen OPCs to treat every paralysis patient in the US for 20 years.
Yes, Bob. The MG report mentioned earnings growth as being a problem with NYMT. When comparing the report of NYMT to PSEC NYMT is better. A problem with some of the reports is they do not give a month for their last update. The report might have been from before the cut you mentioned 3 quarters ago.
MarketGrader gives NYMT a buy rating and in the REIT sector has it 32nd out of 251 companies. It is a good value play trading at below book value. It has generally positive fundamentals. MG says it's dividends are growing too fast potentially straining it's balance sheet.
I would think that NYMT can adjust their dividends down if their earnings cannot support a 15% dividend. Even a 10% dividend with a stable good value company would be very
good, especially in an interest environment where short term bonds pay close to zero.
Taking significant profits is seldom a bad decision. Some times when one waits they slip away. You will likely get a chance again to buy some things you want at a lower price. The stock market is hot right now and some kind of pull back might be on the way.
Staggman. MarkerGrader make the following comment about PSEC in their report.
Prospect Capital Corporations spent $362.44 million in dividends
over the last twelve months, equivalent to 79.80% of its cash flow and 332.64% of its after-tax earnings. By comparison, it paid out 134.68% if its
earnings during the 12 months ended the quarter before last, which means it is paying out significantly more than it is earning, eroding its liquidity
and damaging its balance sheet. This is particularly worrisome in light of its generally poor fundamentals.
I have some PSEC but am not buying more and am watching it closely to see if I should sell what I have. The monthly dividend looks great but if it digs the company into a hole the principle we invest could take another hit. The analyst reports are not always right about companies prospects but I have done better when I pay attention to them than not. Hopefully PSEC will turn things around and do better with it's earnings.
Both SFL and GMLP have high ratings with the analyst evaluations my broker provides.So does STNG. I already own SFL and GMLP and am looking to pick up some STNG if there is a price dip. I was underwater with GMLP when it dipped to the 7s. I could see no reason for to huge price drop in it's financials so I bought more in the 7s and it has now recovered well. It also pays a high dividend. What is your issue with LNG stocks?
I am highly skeptical. However, if you are right I will accept all of your crazy political posts without opposing them. By early 1st quarter of 2017 I will presume by February 15th.
BB. It looks like you are pumping hard against Geron today. Does the 15 cent increase today have you rattled? Jkokao aside, there is a news article that says that Geron is breaching it's 50 day moving average in a bullish way.
What happened with the take over bid of Monsanto by Bayer? Bayer is a German company so if Bayer acquires Monsanto it will be a European company hurt.
Yes, it has been the rhetoric of some parts of the religious community that adult stem cells are not only an alternative to embryonic stem cells but superior in every way. Hematopoietic adult stem cells have been useful for bone marrow transplants but their limited differentiation capacity make them useless in the production of non-blood cell, cell lines. As for induced adult stem cells they have the differentiation capacity but have proven to be highly unstable regressing to their former cell type after some divisions. In rodent studies they caused teratomas. On the other hand there were NO teratomas in about 800 rats treated with Geron/Asterias hESC derived purified OPCs. No teratomas so far in human trials either.
We should not universally condemn the religious community as being a bunch of dummies. The 1st patient in the Geron trial TJ Atchison (spelling?) had the support of his minister and congregation in Alabama.
Stem Cell Inc. has been using ADULT neural stem cells. Adult neural stem cells are few in numbers making them hard to isolate in amounts needed for transplant. They are also limited in their differentiation capacity. On the other hand all of the cells used so far in the Geron and Asterias trial are from ONE blastocyst. I remember some years back when the Oligodendrocyte progenitor cell tech. was still with Geron one of the Geron scientists said that they had enough frozen OPCs to potentially treat every paralysis victim in the USA for 20 years. I never invested in Stem Cell Inc. because I could not see much potential.